The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. [Review]
Citation: Cardiovascular Revascularization Medicine. 21(4):540-548, 2020 04.PMID: 31952919Institution: MedStar Heart & Vascular InstituteonForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Absorbable Implants | *Acute Coronary Syndrome/th [Therapy] | *Cardiovascular Agents/ad [Administration & Dosage] | *Coronary Artery Disease/th [Therapy] | *Drug-Eluting Stents | *Percutaneous Coronary Intervention/is [Instrumentation] | *Sirolimus/ad [Administration & Dosage] | Acute Coronary Syndrome/dg [Diagnostic Imaging] | Cardiovascular Agents/ae [Adverse Effects] | Coronary Artery Disease/dg [Diagnostic Imaging] | Humans | Percutaneous Coronary Intervention/ae [Adverse Effects] | Prosthesis Design | Risk Factors | Sirolimus/ae [Adverse Effects] | Time Factors | Treatment OutcomeYear: 2020Local holdings: Available in print through MWHC library: 2002 - presentISSN:- 1878-0938
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31952919 | Available | 31952919 |
Available in print through MWHC library: 2002 - present
Advances in stent design and the development of bioresorbable polymers have allowed the development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus eluting stent (BP-SES). Over several noninferiority trials, the BP-SES has demonstrated itself to be a safe and effective therapy for obstructive coronary artery disease. This article reviews the current evidence of the efficacy of the BP-SES and examines its performance in high-risk populations, such as patients presenting with ST-segment myocardial infarction, chronic total occlusions, diabetes, and small vessel disease. Copyright (c) 2020 Elsevier Inc. All rights reserved.
English